• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫抑制药物治疗炎症性肠病的历史:起源于西奈山医院。

A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital.

作者信息

Korelitz B I, Present D H

机构信息

Lenox Hill Hospital, Department of Medicine, New York, NY, USA.

出版信息

Mt Sinai J Med. 1996 May-Sep;63(3-4):191-201.

PMID:8692165
Abstract

If the cause of Crohn's disease and ulcerative colitis turns out to be some immunopathologic mechanism, many of the steps leading to such an understanding of their pathogenesis can be attributed to concepts that originated at The Mount Sinai Hospital. Perhaps immodestly, we can claim a role in the acceleration and the acceptance of these concepts; however, many contributions were made by others, including Moschkowitz, Klemperer, Otani, Crohn, Ginzburg, Oppenheimer, Marshak, and Janowitz. This does not mean that clinicians and researchers from other institutions did not contribute to this understanding. As happens so often in medical history, elucidation of many disease processes are serendipitous. The concept of autoimmune diseases was introduced when we were house officers at Mount Sinai. The early days of transplant surgery soon followed along with the introduction by Hitchings and Elion of azathioprine to inhibit rejection. The concept of immunosuppression slowly evolved into possible treatment of any disease thought to be caused by autoimmunity, including those diseases of the bowel, seen so frequently at The Mount Sinai Hospital: ileitis, granulomatous colitis, ileocolitis, and ulcerative colitis. Although most of the world called granulomatous disease of the bowel Crohn's disease, it was only after the deaths of Drs. Crohn, Ginzburg, and Oppenheimer that we accepted this single eponym. However, we will always pay tribute to all three Mount Sinai physicians who wrote the original paper that described the disease.

摘要

如果事实证明克罗恩病和溃疡性结肠炎的病因是某种免疫病理机制,那么在对其发病机制的理解过程中,许多关键步骤都可归功于源自西奈山医院的一些概念。或许这么说有些自夸,但我们可以宣称在这些概念的加速传播和被接受方面发挥了作用;然而,包括莫斯科维茨、克莱姆佩雷尔、大谷、克罗恩、金兹伯格、奥本海默、马沙克和贾诺维茨在内的其他人也做出了许多贡献。这并不意味着其他机构的临床医生和研究人员没有为这种理解做出贡献。在医学史上经常发生的情况是,许多疾病进程的阐明都是偶然的。当我们还是西奈山医院的住院医生时,自身免疫性疾病的概念就被提出了。随后不久,移植手术的早期阶段随之而来,希钦斯和伊莱昂引入了硫唑嘌呤来抑制排斥反应。免疫抑制的概念逐渐演变成可能用于治疗任何被认为由自身免疫引起的疾病,包括在西奈山医院经常见到的肠道疾病:回肠炎、肉芽肿性结肠炎、回结肠病和溃疡性结肠炎。尽管世界上大多数人将肠道肉芽肿性疾病称为克罗恩病,但直到克罗恩博士、金兹伯格博士和奥本海默博士去世后,我们才接受了这个单一的以人名命名的疾病名称。然而,我们将永远缅怀撰写描述该疾病原始论文的三位西奈山医院的医生。

相似文献

1
A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital.免疫抑制药物治疗炎症性肠病的历史:起源于西奈山医院。
Mt Sinai J Med. 1996 May-Sep;63(3-4):191-201.
2
A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at The Mount Sinai Hospital.免疫抑制药物治疗炎症性肠病的历史:起源于西奈山医院。
Mt Sinai J Med. 2000 May;67(3):214-26.
3
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性:意大利炎症性肠病研究小组(IG-IBD)立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
4
Immunosuppressive therapy of inflammatory bowel disease: a historical perspective.炎症性肠病的免疫抑制治疗:历史视角
Gastroenterologist. 1995 Jun;3(2):141-52.
5
The history of surgery for Crohn's disease at The Mount Sinai Hospital.西奈山医院克罗恩病的手术治疗史。
Mt Sinai J Med. 2000 May;67(3):198-203.
6
IBD: immunologic research at The Mount Sinai Hospital.炎症性肠病:西奈山医院的免疫学研究
Mt Sinai J Med. 2000 May;67(3):208-13.
7
Inflammatory bowel disease after 1932.1932年之后的炎症性肠病。
Mt Sinai J Med. 2000 May;67(3):190-7.
8
Immunosuppressive drugs in the treatment of inflammatory bowel disease.免疫抑制药物在炎症性肠病治疗中的应用
Semin Gastrointest Dis. 1998 Jan;9(1):2-9.
9
Review article: monitoring of immunomodulators in inflammatory bowel disease.综述文章:炎症性肠病中免疫调节剂的监测
Aliment Pharmacol Ther. 2005 Feb 15;21(4):307-19. doi: 10.1111/j.1365-2036.2005.02343.x.
10
Planting seeds of knowledge about inflammatory bowel disease: half a century of science, prescience, and prophecy in the pages of Mount Sinai s Journal.播撒关于炎症性肠病的知识种子:《西奈山杂志》半个世纪的科学、先见之明与预言
Mt Sinai J Med. 2001 Mar;68(2):79-87.

引用本文的文献

1
Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.在系统评价中使用病例报告和不良事件报告系统:克服障碍评估克罗恩病药物与肝脾 T 细胞淋巴瘤之间的关联。
Syst Rev. 2013 Jul 5;2:53. doi: 10.1186/2046-4053-2-53.
2
Thiopurines in IBD: What Is Their Mechanism of Action?IBD中的硫嘌呤:其作用机制是什么?
Gastroenterol Hepatol (N Y). 2010 Jul;6(7):435-6.
3
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
克罗恩病中免疫抑制剂使用增加对肠道手术需求的影响。
Gut. 2005 Feb;54(2):237-41. doi: 10.1136/gut.2004.045294.